TNK for Monocular Blindness (Central Retinal Artery Occlusion)
Based on the most recent high-quality evidence, TNK (tenecteplase) should NOT be used for acute monocular blindness from central retinal artery occlusion (CRAO) outside of clinical trials, as the 2026 TenCRAOS randomized controlled trial demonstrated no benefit over aspirin and was associated with serious safety concerns including fatal intracranial hemorrhage.
Critical Evidence from the Definitive Trial
The TenCRAOS trial 1, published in 2026 in the New England Journal of Medicine, represents the highest quality evidence available—a phase 3, double-blind, randomized controlled trial specifically designed to answer this question. The results are definitive and concerning:
- No efficacy benefit: Only 20% of TNK-treated patients achieved vision recovery (≥20/100) at 30 days versus 24% with aspirin alone (risk difference -3.7%, p=0.69)
- Serious safety signal: One fatal intracranial hemorrhage occurred in the TNK group
- Treatment window: Patients were treated within 4.5 hours of symptom onset—the theoretically optimal window
This trial directly contradicts the equipoise suggested in earlier 2021 AHA guidelines 2, which were based on observational data and meta-analyses that preceded this definitive randomized trial.
Why the Guidelines Are Now Outdated
The 2021 AHA Scientific Statement 2 acknowledged that "there is equipoise in the utility of intravenous tPA for CRAO" and noted that three randomized trials were ongoing, including TenCRAOS. That equipoise has now been resolved—the trial failed to show benefit and demonstrated harm.
The guidelines mentioned that TNK was being studied in the Ten-CRAOS trial 2, but those results are now available and negative. The FDA label for TNK 3 only approves it for ST-elevation myocardial infarction, not for CRAO.
Conflicting Observational Data
Several retrospective studies suggest potential benefit:
- A 2025 retrospective study 4 showed better visual outcomes with TNK versus medical management (OR 6.70 for >20/200 vision)
- A 2024 telemedicine pathway study 5 reported 54.3% of TNK-treated patients had ≥0.3 logMAR improvement versus 28% untreated
- Small case series 6, 7 reported safety without hemorrhagic complications
However, these observational studies are fundamentally limited by:
- Selection bias (healthier patients more likely to receive treatment)
- Lack of randomization
- Small sample sizes
- Publication bias favoring positive results
The randomized controlled trial 1 supersedes all observational evidence—this is the hierarchy of evidence in action.
Clinical Approach to Acute Monocular Blindness
When a patient presents with sudden, painless monocular vision loss:
Immediate Triage (Within Minutes)
- Emergency department transfer for ophthalmologic examination and stroke workup 8, 2
- Exclude giant cell arteritis (GCA): Check temporal artery, ESR/CRP if age >50 or high suspicion 2
- Confirm CRAO diagnosis: Funduscopic exam showing retinal whitening, cherry-red spot, relative afferent pupillary defect 2
Acute Management (Within 4.5 Hours)
- Do NOT administer TNK based on TenCRAOS results 1
- If GCA suspected: Immediate high-dose IV methylprednisolone (1g daily) 2
- Aspirin 300mg is reasonable as it was the comparator in TenCRAOS 1
- CT brain to evaluate for concurrent cerebral stroke (present in 20-24% of CRAO patients) 8
Critical Pitfall
The 2020 Ophthalmology PPP 8 states "thrombolytic treatments have never been proven to be effective" and notes evidence is "controversial and limited to level II data." This conservative stance has now been validated by the negative TenCRAOS trial 1.
Stroke Risk Assessment
CRAO is a stroke equivalent requiring urgent neurologic evaluation 8, 2:
- 3-6% risk of ischemic stroke in first 1-4 weeks
- 19-25% have silent brain infarction on MRI
- Up to 70% have significant carotid stenosis discovered
Workup should include:
- MRI brain with diffusion-weighted imaging (more sensitive than CT) 8
- Carotid imaging
- Cardiac evaluation for embolic source
- Vascular risk factor assessment
Why Not Intra-arterial Thrombolysis?
The EAGLE trial of intra-arterial tPA was stopped early for futility 2. The ophthalmic artery (1.3mm) and central retinal artery (160μm) are too small for mechanical thrombectomy 2. Intra-arterial approaches carry risks of arterial dissection, catheter complications, and distal embolization 2.
Bottom Line
TNK should not be used for CRAO based on the definitive 2026 TenCRAOS randomized trial showing no benefit and serious bleeding risk. Focus instead on:
- Rapid stroke workup and secondary prevention
- GCA exclusion and treatment if present
- Aspirin and risk factor modification
- Patient counseling that natural history is poor (only 17% achieve functional vision) 2
The observational data suggesting benefit 4, 5, 6 cannot overcome the negative randomized trial 1—this is fundamental to evidence-based medicine.